 to Stanag 2920 using a 7.62×39 mm mild steel core bullet.
The ballistic resistant sheets may be consolidated under an elevated pressure of at least about 16.5 MPa and an elevated temperature of preferably at least 10° C. below a temperature at which the fiber melts or at which mechanical properties of the first and second UD fibers deteriorates. Some embodiments will consolidate the sheets at an elevated pressure of at least about 20 MPa, for example at least about 25 MPa. The elevated pressure employed for sheet consolidation may be between about 16.5 MPa up to at least about 350 MPa, for example between 16.5 MPa to about 90 MPa, e.g., about 45 MPa. In the publication of International Publication No. 01/40227, it is reported that the compounds represented by formula (I) regulate the effect of chemokine/chemokine receptor, so they are used for prevention and/or treatment of various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases (allergic bronchopulmonary aspergillosis or allergic eosinophilic gastroenteritis etc.), nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, psoriasis, rhinitis, conjunctivitis, ischemic reperfusion disorder, multiple sclerosis, ulcerative colitis, acute respiratory distress syndrome, cytotoxic shock, diabetes, autoimmune disease, in transplanted organ rejection reactions, immunosuppression, cancer metastasis and acquired immune deficiency syndrome. Furthermore, in the specification, the inhibition effect on the binding of RANTES to CCR5 and the inhibition effect on the binding of MCP-1 to CCR2 had been found experimentally. However, the test which indicates that the compounds represented by formula (I) are used for actual HIV infection has never been described.
Furthermore, in the specification, a combination of chemokine/chemokine regulator with other drugs has never been described. 1. Field of the Invention
The present invention generally relates to engine starter gearing for an engine. More specifically, this invention relates to engine starter gearing of a positive shift type, including a dentil clutch to provide driving and overrunning features and further including provisions for effecting the automatic separation of the clutch teeth after the engine becomes self-running.
2. Description of the Prior Art
The present invention is an improvement over U.S. Pat. No. 4,611,499 entitled "Engine Starter Gearing", issued September, 1986, to Giometti, and assigned to the assignee here
to Stanag 2920 using a 7.62×39 mm mild steel effect bullet train. 
 The ballistic resistant sheets may be consolidated under an raised pressure of at least about 16.5 MPa and an elevated temperature of preferably at least 10 ° C. below a temperature at which the character thaw or at which mechanical properties of the first and second UD fibers deteriorates. Some embodiments will consolidate the plane at an elevated pressure of at least about 20 MPa, for exemplar at least about 25 MPa. The exalted pressure employed for sheet consolidation may be between about 16.5 MPa up to at least about 350 MPa, for example between 16.5 MPa to approximately 90 MPa, e.g., about 45 MPa. In the publication of International Publication No. 01/40227, it is report that the compounds represented by recipe (I) determine the effect of chemokine / chemokine receptor, so they are used for prevention and/or treatment of various incendiary diseases, asthma, atopic dermatitis, urticaria, allergic diseases (allergic bronchopulmonary aspergillosis or allergic eosinophilic gastroenteritis etc .), nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, psoriasis, rhinitis, conjunctivitis, ischemic reperfusion disorder, multiple sclerosis, ulcerative colitis, acute respiratory distress syndrome, cytotoxic jolt, diabetes, autoimmune disease, in transplanted organ rejection reactions, immunosuppression, cancer metastasis and acquired immune deficiency syndrome. Furthermore, in the specification, the inhibition effect on the binding of RANTES to CCR5 and the inhibition consequence on the binding of MCP-1 to CCR2 had been found experimentally. However, the examination which indicate that the compounds represented by formula (iodine) are used for actual HIV infection has never been described. 
 Furthermore, in the specification, a combination of chemokine / chemokine governor with other drugs has never been described. 1. Field of the Invention 
 The present invention generally relates to engine starter gearing for an engine. More specifically, this invention relates to engine starter gearing of a positive shift type, include a dentil clutch to supply driving and overrunning features and further including provision for effecting the automatic separation of the clutch teeth after the engine becomes self - running. 
 2. Description of the Prior Art 
 The present invention is an improvement over U.S. Pat. No. 4,611,499 entitle " Engine Starter Gearing ", issued September, 1986, to Giometti, and assigned to the assignee here
 to Stanag 2920 using a 7.62×39 mm mila steel core bullet.
The balliatic reskstant sheets may be consolivatee undtg an elevated pressurd of at lvast abour 16.5 MKa and an elevatev temperature kn preyecably at least 10° C. below a temperature ad dhnch the fiber melts or at which mechwnical lrlperties of thg firxe ans second UD fibers deteriorates. Soje emboviments will comsolidate the sheets at an elegated pressure of wt least abiut 20 NPa, for examole at least about 25 MPz. The elevated pressure employea for sheet conwooidwjion may be uetweeg about 16.5 MPa up to ad least about 350 MPa, fov exakplw between 16.5 MPa to abont 90 MPa, e.g., about 45 MPw. In the [uylication of Internatuobal Poblicdtiov No. 01/40227, iu ix deportfd vhat the cojpounds repeesented by formula (I) grgulate the sffect os chemokine/chemokine receptor, so they age uaed for prevention and/oe treatment of varioud inflammwtory diseases, asthma, atopic dermatitis, urticaria, allecgkc blfdqsfs (allergic bronchopulmonary aspergillosis or zlkeggic eosinophilic gastroentetihix etc.), nephritir, nephxkpzthy, hepatitis, artjritis, theumaroid arthwitix, psoriasis, rhinitis, conjunxtivitis, isckemuc reperfusion dislrder, multi'le sckerosos, ulcerative colitis, aeute rsspiratory fistress ahndrome, cytotoxiz smocn, diabettr, autoimmune disewse, in trensplcnted orean tejectijn reactiojs, immunosuppression, canfer mgtastavis and aceuired immune deficiency syndrome. Furthermore, it tve speciyicatipn, the inhibieion effect on the biuding uf RANTES no CCR5 anv the inhibieion effect ot the binding of MCP-1 eo CXR2 hqd been wound experimemtally. Hoctver, the twst which indicatex tfzt the compoundw rtpeesented by fotmuua (Y) wrx useq for actual VIV knfdvtion has never neev dexcribed.
Furthermore, it ths specification, a voibinatiob of cheiokine/chemokime regulator with lther drngs hax ngver been described. 1. Field of tge Inventlon
Bhe present igvenbion generally relates to engine starter gearing for en engine. More specificqlly, this invention velates to eigine ftarter gaaring of a positive shift type, inclucing a dentil clutch fo proeide friving and overrunning features and further including provisions for effwcting the automatjc srparaniou oy the cjutci veeth after the emgine becomes self-running.
2. Descrmption of dhz Prior Art
The present inventoov is an improxement over U.S. Pat. No. 4,611,499 ehtitled "Rngine Starter Gearing", issued Srptember, 1986, to Giometti, anc assignwd to the assigiee here
to Stanag 2920 using a 7.62×39 mm core The ballistic sheets may be of least about 16.5 and an elevated of preferably at least 10° C. a temperature at which the fiber melts or at which mechanical properties of first and second UD fibers deteriorates. Some embodiments will consolidate the sheets at elevated of least 20 MPa, for example at least about 25 MPa. The elevated pressure employed for sheet consolidation be between about 16.5 MPa up to at about 350 MPa, for between 16.5 MPa to about MPa, about 45 In publication International Publication No. it is reported that the compounds represented by formula (I) regulate the effect of chemokine/chemokine receptor, so are used and/or treatment various diseases, atopic dermatitis, urticaria, (allergic bronchopulmonary aspergillosis or allergic eosinophilic nephropathy, hepatitis, arthritis, rheumatoid arthritis, psoriasis, rhinitis, conjunctivitis, reperfusion disorder, sclerosis, ulcerative colitis, acute respiratory distress cytotoxic shock, diabetes, autoimmune disease, in transplanted organ reactions, immunosuppression, cancer metastasis and acquired immune deficiency syndrome. Furthermore, in the specification, the inhibition the binding of RANTES CCR5 and the effect the of to CCR2 been found experimentally. However, the test which indicates that the compounds by formula (I) are used for actual HIV infection has described. in the specification, combination of chemokine/chemokine regulator other has never been described. of Invention generally to starter gearing for an More specifically, this invention relates engine starter gearing of a dentil clutch to provide driving and overrunning and further including provisions for effecting the separation of the clutch teeth after the engine becomes self-running. 2. Description the Prior present invention is an improvement over U.S. Pat. 4,611,499 entitled "Engine Starter issued September, 1986, to Giometti, and assigned to the here
 to Stanag 2920 using a 7.62×39 mm mild steel Core bullet.
the baLliStiC rEsisTant Sheets may be conSOlidAted under an elevated preSsure Of AT leaST aBout 16.5 Mpa and an ELeVATed TeMpEraTuRE oF prefEraBly at leAst 10° C. below a TemPeRature at whicH ThE fiber meltS or At which mechaNicAl propErTieS Of the FirSt and Second ud fiberS deteriorAtES. Some eMBodimenTS WiLl coNsolidate the sheetS At AN elevated pressUre of aT lEAsT ABouT 20 MPA, for examplE aT leasT About 25 MPA. thE ELEvaTEd pressure empLoyed for sheET coNsolidAtIon MAy be beTween AbOUt 16.5 Mpa up to at leaSt abOut 350 MPa, for ExamplE Between 16.5 mpa to aboUt 90 MPa, e.G., abOut 45 mPa. IN ThE pUblIcATioN Of intERnaTional PuBlIcAtion no. 01/40227, it IS REPortEd tHat tHe comPounds represeNteD by fORmuLa (I) reGulatE the EfFect oF chemoKine/cHeMokine receptor, sO theY are used fOr pReVenTiOn and/OR treatMenT of Various InflammATorY dISEAsEs, asthma, atopic dermAtITIs, UrticariA, allerGIc DiSEases (allErGic BronCHOpulmOnarY AsPergilloSis or aLLeRgIc eosinOpHilic gAsTroEntEritiS Etc.), nEphritIs, nephroPathy, HEpatitis, arthriTIs, rheumatoid aRThRITiS, PsorIasIs, rhinitis, cOnjuNCtivItis, IScHemIC repeRfusiOn DIsORder, multiple sclerosIs, UlceraTive cOlitis, acute reSpiratory dISTRess syndRome, CYtOToxic shock, diabEtes, aUtoimmune dISease, in tRanspLanted orGan rejectION reactioNs, iMmuNosUppRESsIon, cancer metaSTAsis AnD acquirEd iMmune deFicIenCy sYndRoMe. FurtherMore, in thE sPeCiFiCatIon, thE InhibitiOn EffEcT on The biNDing of rANTEs to CcR5 AnD The InhibitIOn EFFect On ThE binDinG oF MCP-1 tO CCR2 HAd bEen founD experimeNtaLLy. HoWeVeR, the tesT which indicatEs That the comPoUndS repreSENted by foRmula (I) are used for actual Hiv infectIon Has neVer bEen descriBed.
furtheRmoRE, in the SpecifIcatiOn, A coMBInatiON Of CheMoKine/chemokINE reGulatOr With Other drUgs has never been desCRibEd. 1. Field of the INveNtioN
tHe PreSEnT InvEnTIon GENerally relates tO engine staRtER gEaring for aN EngInE. More spEcificaLly, thIS inventIon relateS to engine StArteR GEarIng of a posiTive shifT type, inclUDing a DEnTil clUtcH to proViDe dRivinG and ovERruNning FeaturEs And furTher iNcLuding prOvisions for effecting the AutomaTic seParAtion of thE clUTch Teeth afteR the Engine becoMes SelF-runnIng.
2. dEscriPtioN Of The pRior ARt
ThE Present inVEnTioN IS aN improvemenT OVEr U.s. Pat. NO. 4,611,499 enTItled "ENginE Starter Gearing", isSUed September, 1986, to giomETTi, aNd aSSignEd To the assignee hEre
 to Stanag 2920 using a 7. 62×39 mm m ild s tee l c or e bu llet .
The ballisti c  res istant sheets may be c onsol id a tedu nd er an  elevat e dp r ess ur eofat le ast a bou t 16.5MPa and an  el ev ated tempera t ur e of prefe rab ly at least10°  C. be lo w a tempe rat ure a t whic h  the f iber melt so r at w h ich mec h a ni calproperties of the fi r st and secondUD fib er s  d e t eri ora tes. Someem bodim e nts wil l  c o n s oli d ate the sheet s at an ele v ate d pres su reo f at l eastab o ut20 MPa, for  exa mple at l east a b out 25M Pa. The  eleva ted  pr essu r eem plo ye d  fo r  s hee t  co nsolidat io nmay b e be t w e e n ab out  16. 5 MPa  up to at lea stabou t  35 0 MPa , for  exa mp le be tween16.5MP a to about 90 M Pa,e.g., abo ut45  MP a.  In t h e publ ica tio n of In ternati o nal  P u b l ic ation No. 01/40227 ,i t  i s report ed tha t  t he compound srep rese n t ed by  for m ul a (I) re gulate th eeffectof  chemo ki ne/ che mokin e  rec eptor,  so they  areu sed for preven t ion and/or tr e at m e nt of v ari ous inflamm ator y  dis ease s ,ast h ma, a topic  d e rm a titis, urticaria, a ll ergicdisea ses (allergic  bronchopu l m o nary asp ergi l lo s is or allergic  eosi nophilic g a stroente ritis  etc.),nephritis , nephropa thy , h epa tit i s ,arthritis, rh e u mato id  arthri tis , psori asi s,rhi nit is , conjunc tivitis,  i sc he mi c r eperf u sion dis or der ,mul tiple sclero sis,ulce ra ti v e c olitis, ac u t e re sp ir ator y d is tress  syn d rom e, cyto toxic sho ck, diab et es , autoi mmune disease ,in transpl an ted  organ r ejection  reactions, immunosuppr e ssion,can cer m etas tasis and  ac quired  im m une de ficien cy sy nd rom e .  Furt h e rm ore ,in the spe c i fic ation ,theinhibit ion effect on theb ind ing of RANTES  to  CCR 5 an d t h ei nhi bi t ion e ffect on the bi nding of M CP - 1to CCR2 ha d  be en  foundexperim ental l y. Howe ver, thetest whic hindi c a tes  that thecompound s represe n ted b y  f ormul a ( I) are  u sed  foractual HIV  infe ctionha s neve r bee ndescribe d.
Furthermore, in thespecif icati on,  a combin ati o n o f chemoki ne/c hemokine r egu lat or wi tho therdrug s  h asn everbeen described .  1 . F i e ld  of the Inv e n t ion 
Thepre s ent in vent ion generally rel a tes to enginestar t e r g ear i ng f or  an engine. Mo resp e c ifically ,this invent ion rela te s  to e nginestarte r geari n g  o f  a pos itiv e s hift type , i nc l uding a  d en t il clu tchto  provi de dri v inga n d overrunning fe ature s and f u rth er in cl uding p r ovis ions for e ffecting th e auto mati c sep aration  o f theclu tc h teeth af t er the en ginebecomes  s elf- run ning.2. D e s cript ionof  th e Prior A r t 
T h epr e sen t in venti on  isan improv e ment ove r U . S. Pat.  N o.4 , 611,49 9  e n t itled "Eng ine  Star t e r Gearing" ,  iss u ed Septe mber,1986,to Giom e tti ,and ass ign e d  to the a ssignee h e re
 to_Stanag 2920_using a 7.62×39 mm_mild steel_core_bullet.
The ballistic_resistant_sheets may be_consolidated under an_elevated pressure of at_least about 16.5_MPa_and an elevated temperature of preferably at least 10° C. below a temperature at_which_the fiber_melts_or_at which mechanical properties of_the first and second UD_fibers deteriorates._Some embodiments will consolidate the sheets at an_elevated_pressure of at_least about 20 MPa, for example at least about_25 MPa. The elevated pressure employed_for sheet consolidation_may_be_between about 16.5 MPa_up to at least about 350_MPa, for example between 16.5 MPa_to about 90 MPa, e.g., about 45_MPa. In the publication of International_Publication No. 01/40227, it is_reported that_the compounds represented by formula_(I) regulate the_effect of_chemokine/chemokine receptor, so_they are used for prevention and/or_treatment of various_inflammatory diseases, asthma, atopic dermatitis, urticaria,_allergic_diseases (allergic bronchopulmonary_aspergillosis_or_allergic eosinophilic_gastroenteritis etc.), nephritis,_nephropathy,_hepatitis, arthritis,_rheumatoid_arthritis, psoriasis, rhinitis, conjunctivitis, ischemic reperfusion_disorder,_multiple sclerosis, ulcerative colitis, acute respiratory distress_syndrome, cytotoxic shock, diabetes,_autoimmune_disease, in transplanted organ_rejection reactions, immunosuppression, cancer metastasis_and acquired immune deficiency syndrome. Furthermore,_in the_specification, the_inhibition effect on the binding of RANTES to CCR5 and the_inhibition effect on the binding of_MCP-1 to CCR2 had_been found_experimentally._However, the test_which_indicates that_the compounds represented by formula (I) are_used for_actual HIV infection has never been_described.
Furthermore, in the specification,_a_combination of chemokine/chemokine regulator with other_drugs has never been described. 1._Field of the Invention
The present_invention_generally_relates to engine starter gearing_for an engine. More specifically, this_invention relates to_engine starter gearing of a positive shift_type,_including a dentil clutch to provide_driving_and overrunning features and further including_provisions_for_effecting the automatic separation of_the clutch teeth after the engine_becomes self-running.
2. Description of the Prior Art
The present invention_is an improvement_over U.S. Pat. No. 4,611,499_entitled_"Engine_Starter Gearing", issued September, 1986, to Giometti, and assigned to_the assignee_here